Correction of acidosis in hemodialysis patients. Effects on protein metabolism, investigated by tracer technique and messenger-ribonucleic acid determination for ubuquitin and proteasome subunits.
| ISRCTN | ISRCTN27844532 |
|---|---|
| DOI | https://doi.org/10.1186/ISRCTN27844532 |
| Protocol serial number | N/A |
| Sponsor | Karolinska University Hospital (Sweden) |
| Funders | Swedish Medical Research Council (ref: 11243 and 04210), Gambro AB, Baxter Inc., U.S. National Institutes of Health (R01 DK37175) |
- Submission date
- 29/03/2006
- Registration date
- 03/07/2006
- Last edited
- 26/07/2007
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Nutritional, Metabolic, Endocrine
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Erland Löfberg
Scientific
Scientific
Karolinska University Hospital
Department of Renal Medicine
Solna
Stockholm
SE-171 76
Sweden
| Phone | +46 (0)85 1773768 |
|---|---|
| erland.lofberg@karolinska.se |
Study information
| Primary study design | Interventional |
|---|---|
| Study design | Randomised, controlled, crossover design |
| Secondary study design | Randomised controlled trial |
| Scientific title | |
| Study objectives | Metabolic acidosis stimulates muscle protein breakdown, correction of acidosis results in decreased protein breakdown. |
| Ethics approval(s) | Approved by the Ethics Committee of Karolinska Institute at Huddinge University Hospital on 11/01/1993, reference number: 196/96 |
| Health condition(s) or problem(s) studied | End-stage renal failure |
| Intervention | Adjustments of acid-base balance - in each patient, protein turnover will be measured twice, at a standard bicarbonate concentration of <19 mmol/l and >25 mmol/l respectively, with an interval between the two measurements (random order) of 3-4 weeks. The acid-base status will be altered by adjusting the dose of bicarbonate (oral and/or via dialysis) and protein turnover will be measured when the predialysis bicarbonate level have been low or normal for at least one week. |
| Intervention type | Other |
| Primary outcome measure(s) |
Muscle protein turnover |
| Key secondary outcome measure(s) |
1. messenger-Ribonucleic Acid (mRNA) for ubuquitin and proteasome subunits |
| Completion date | 31/12/1998 |
Eligibility
| Participant type(s) | Patient |
|---|---|
| Age group | Adult |
| Lower age limit | 18 Years |
| Sex | All |
| Target sample size at registration | 16 |
| Key inclusion criteria | 1. Clinically stable hemodialysis patients 2. >18 Years of age |
| Key exclusion criteria | 1. Clinically obvious malnutrition 2. Ongoing infection 3. Diabetes mellitus 4. Untreated congestive heart failure 5. Treatment with corticosteroids or other immunosuppressive agents |
| Date of first enrolment | 01/04/1997 |
| Date of final enrolment | 31/12/1998 |
Locations
Countries of recruitment
- Sweden
Study participating centre
Karolinska University Hospital
Stockholm
SE-171 76
Sweden
SE-171 76
Sweden
Results and Publications
| Individual participant data (IPD) Intention to share | No |
|---|---|
| IPD sharing plan summary | Not provided at time of registration |
| IPD sharing plan |
Study outputs
| Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
|---|---|---|---|---|---|
| Results article | Results: | 01/09/2006 | Yes | No |